**Background of MHC-E Recombinant Proteins**
MHC-E (Major Histocompatibility Complex class E) recombinant proteins are engineered molecules derived from the non-classical MHC-E locus, a component of the mammalian immune system. Unlike classical MHC-I molecules (e.g., HLA-A, -B, -C), which present peptide antigens to T-cells, MHC-E is primarily involved in immune regulation and interacts with natural killer (NK) cells via receptors like CD94/NKG2A. MHC-E exhibits limited polymorphism and can bind both self-peptides and pathogen-derived peptides, making it a unique player in bridging innate and adaptive immunity.
Recombinant MHC-E proteins are generated using biotechnological methods, such as expression in mammalian or insect cell systems, to ensure proper folding and post-translational modifications. These proteins retain the α1/α2 domains critical for peptide binding and receptor interactions. Researchers often load them with specific peptides (viral or tumor-associated) to study their structural and functional properties.
The interest in MHC-E stems from its dual role in immune evasion and surveillance. Pathogens like cytomegalovirus exploit MHC-E to avoid NK cell detection, while cancer cells may overexpress MHC-E to suppress immune responses. Conversely, MHC-E-restricted T-cell responses have been identified, suggesting therapeutic potential. Recombinant MHC-E proteins are pivotal tools for developing vaccines, immunotherapies, and diagnostics, particularly in contexts where conventional MHC-I pathways are compromised.
Current research focuses on deciphering MHC-E’s peptide-binding motifs, optimizing recombinant production for clinical use, and exploring its utility in cross-presenting antigens to enhance immune targeting. Challenges include ensuring stability and scalability while maintaining biological activity. Overall, MHC-E recombinant proteins represent a promising frontier in immunology and translational medicine.
以下是关于MHCC(人肝癌细胞系)重组蛋白研究的3篇参考文献摘要整理：
---
1. **文献名称**：*Expression and functional analysis of recombinant AFP/TGF-β1 fusion protein in MHCC97H hepatocellular carcinoma cells*
**作者**：Li X, Wang Y, et al.
**摘要**：该研究构建了AFP(甲胎蛋白)与TGF-β1的重组融合蛋白，并在MHCC97H肝癌细胞中验证其表达。实验表明该重组蛋白通过调控Wnt/β-catenin信号通路抑制肝癌细胞侵袭迁移，为靶向治疗提供新策略。
2. **文献名称**：*Recombinant human endostatin suppresses angiogenesis and metastasis in MHCC97L via downregulating VEGF/MMP-9 pathway*
**作者**：Zhang R, Chen H, et al.
**摘要**：研究探讨重组人内皮抑素(rhES)对低转移性MHCC97L细胞的作用，发现rhES通过抑制VEGF和MMP-9表达，显著降低肿瘤血管生成及转移潜能，提示其在抗肝癌转移中的潜在价值。
3. **文献名称**：*Production of bioactive recombinant HMGB1 in MHCC and its role in promoting tumor inflammation*
**作者**：Guo S, Liu T, et al.
**摘要**：本研究在MHCC细胞中成功表达具有生物活性的重组HMGB1蛋白，证实其通过激活TLR4/NF-κB通路增强肿瘤微环境的炎症反应，可能参与肝癌免疫逃逸机制。
---
**说明**：以上文献为模拟示例，实际研究中需通过PubMed、Web of Science等平台以关键词“MHCC recombinant protein”或“hepatocellular carcinoma recombinant protein”检索最新论文。建议优先选择近五年内发表于《Hepatology》《Cancer Research》等高影响力期刊的研究。
MHCC recombinant protein refers to a class of engineered proteins derived from the MHCC (Metastatic Human Hepatocellular Carcinoma) cell line or related hepatocellular carcinoma (HCC) models. These proteins are designed to mimic or modulate specific molecular pathways involved in liver cancer progression, particularly metastasis. HCC is a leading cause of cancer-related deaths globally, with metastasis being a major challenge in treatment. The MHCC cell line, notably MHCC97H and its sublines, is widely used in HCC research due to its high metastatic potential, enabling studies on invasion, angiogenesis, and drug resistance.
Recombinant MHCC proteins are typically produced using genetic engineering techniques, such as expression in bacterial, yeast, or mammalian systems (e.g., CHO cells). They often target key biomarkers or signaling molecules implicated in HCC, such as VEGF, EGFR, or Wnt/β-catenin pathway components. For example, recombinant proteins may serve as decoy receptors to inhibit pro-metastatic signals or as diagnostic tools to detect circulating tumor markers.
Applications include therapeutic development, biomarker discovery, and mechanistic studies. In preclinical research, these proteins help elucidate metastasis mechanisms or evaluate drug efficacy. Clinically, they hold potential as targeted therapies or components of immunotherapies. Challenges include ensuring stability, bioavailability, and specificity in vivo. Current efforts focus on optimizing delivery systems (e.g., nanoparticles) and reducing off-target effects. As personalized medicine advances, MHCC recombinant proteins may contribute to tailored treatments for HCC patients with specific genetic or molecular profiles. Their role in combination therapies, alongside chemotherapy or immune checkpoint inhibitors, is also being explored to address drug resistance and improve outcomes.
×
